Review Compares Outcomes, Safety for Once-Weekly GLP-1RAs

Share this content:
Review Compares Outcomes, Safety for Once-Weekly GLP-1RAs
Review Compares Outcomes, Safety for Once-Weekly GLP-1RAs

TUESDAY, Dec. 8, 2015 (HealthDay News) -- Cardiometabolic outcomes and safety vary among different once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) treatments, according to a review published online Dec. 8 in the Annals of Internal Medicine.

Francesco Zaccardi, M.D., from the University of Leicester in the United Kingdom, and colleagues conducted a systematic review to summarize evidence for the cardiometabolic efficacy and adverse effects of once-weekly GLP-1RAs in adults with type 2 diabetes. Data were included from 34 trials with 21,126 participants.

The researchers found that all once-weekly GLP-1RAs reduced hemoglobin A1c (HbA1c) and fasting plasma glucose compared with placebo, while 20-mg taspoglutide, once-weekly exenatide, and 1.5-mg dulaglutide reduced body weight. Among once-weekly GLP-1RAs, the greatest differences for HbA1c; fasting plasma glucose; and body weight were found for 1.5-mg dulaglutide and 10-mg taspoglutide; once-weekly exenatide and albiglutide; and 20-mg taspoglutide and 0.75-mg dulaglutide, respectively. For blood pressure, blood lipid levels, and C-reactive protein levels, clinically marginal or no differences were observed. Compared with albiglutide and dulaglutide, once-weekly exenatide increased heart rate. The risk for hypoglycemia was similar among once-weekly GLP-1RAs, whereas 20-mg taspoglutide correlated with the greatest risk for nausea (odds ratios, 1.9 to 5.9).

"In conclusion, available data suggest differences in cardiometabolic outcomes and safety among once-weekly GLP-1RAs," the authors write. "Further randomized controlled trials with direct comparisons of once-weekly GLP-1RAs can help better clarify their comparative tolerability and efficacy and inform the choice among these newly available glucose-lowering agents."

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi Aventis, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »